Almirall SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Almirall SA with three other
pharmaceutical manufacturers in Europe:
sales of 789.60 million Euro [US$878.31 million]
of which 44%
Swedish Orphan Biovitrum AB (publ)
(9.14 billion Swedish Kronor [US$965.62 million]
of which 100%
was Sales of Pharmaceuticals), and
based in the United Kingdom
(£620.50 million [US$807.94 million]
of which 39%
was Interventional Medicine).
Almirall SA reported sales of 756.93 million Euro (US$841.98 million)
December of 2018.
increase of 18.4%
versus 2017, when the company's sales were 639.38 million Euro.
Despite this increase, sales are still
below the level achieved in 2016, when Almirall SA
reported sales of 764.36 million Euro.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Almirall SA had sales
of 692.89 million Euro.
Sales of Licenses saw an increase
that was more than double the company's growth rate: sales were up
38.5% in 2018, from
79.83 million Euro to 110.59 million Euro.
Almirall SA also saw significant increases in sales in
Dermatology (up 32.9% to 109.88 million Euro)
Not all segments of Almirall SA experienced an increase in sales in 2018:
sales of Corporate fell 0.1% to 25.93 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).